NCT05060003View on ClinicalTrials.gov

Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 8, 2022

Primary Completion Date

November 27, 2023

Study Completion Date

November 27, 2023

Conditions
Stage II Melanoma
Interventions
DRUG

Atezolizumab

Atezolizumab is provided by Genentech.

DRUG

Tiragolumab

Tiragolumab is provided by Genentech.

DEVICE

Signatera Assay

"* To detect residual disease or to determine cancer recurrence with ctDNA~* Step 2 screening (4-12 weeks after date of surgery), cycle 3 day 1, cycle 6 day 1, cycle 9 day 1, cycle 12 day 1, and end of treatment (optional)"

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Washington University School of Medicine

OTHER